Latest news with #PopulationHealth
Qatar Tribune
5 days ago
- Health
- Qatar Tribune
QU celebrates first PhD graduates of its Health Sciences programme
Tribune News Network Doha Qatar University (QU) has announced the graduation of the first two students from its PhD in Health Sciences programme, marking a significant milestone for QU Health and its commitment to advancing research aligned with Qatar's national health priorities. The PhD in Health Sciences, governed by the 'Health Sector Graduate Studies Office', offers two specialised tracks: Biomedical and Pharmaceutical Research and Clinical and Population Health Research. This year's achievement highlights the graduation of one student from each track, signaling the program's growing impact on national and global health research. Dr. Jazeel Abdulmajeed is the first graduate of the Clinical and Population Health Research track. His research addressed the appropriate use of effect measures in clinical research, proposing improvements that enhance the interpretation and reliability of healthcare evidence, particularly in observational studies and meta-analyses. Dr. Abdulmajeed said, 'My PhD aimed to improve the methodological foundations of clinical research to ensure that health decisions are based on accurate and meaningful evidence. I am honoured to be the first graduate of this track and proud to contribute to the advancement of research excellence at QU.' Dr. Abdulmajeed was supervised by Prof. Suhail Doi, head of the Department of Population Medicine at the College of Medicine. Prof. Doi said, 'Dr. Abdulmajeed's research offers important methodological solutions that improve how we assess and apply healthcare data in real-world settings.' In parallel with his academic work, Dr. Abdulmajeed also contributes to the Business and Health Intelligence Department at the Primary Health Care Corporation and has served in various roles at the Ministry of Public Health. On her part, Nadin Younes, the first graduate of the Biomedical and Pharmaceutical Research track, focused her doctoral work on improving disease diagnostics. Her research led to the development of rapid, cost-effective tools to detect Norovirus and Hepatitis E Virus — pathogens that pose a high risk in densely populated and resource-limited environments. 'I aimed to design accessible and affordable diagnostic tools that could support early detection and better outbreak control,' Younes explained. 'I'm thankful to my supervisor and the supportive research environment at QU Health that made this possible.' Supervised by Prof. Gheyath Nasrallah, professor of Immunology and Microbiology at the College of Health Sciences, her work resulted in the creation of a novel lateral flow assay for Norovirus, which is now undergoing regulatory review with support for potential commercialisation. A complementary test for Hepatitis E Virus is also nearing completion. 'Nadin's research addresses a pressing public health need and demonstrates the potential of applied biomedical innovation in Qatar,' said Prof. Nasrallah. Dr. Muhammad Abdul Hadi, coordinator of the Clinical and Population Health Research track, emphasised the broader importance of this achievement, 'This graduation signifies more than academic success — it reflects our programme's vision of developing researchers who are equipped to address complex health challenges. We are proud of our graduates for setting a strong precedent for future cohorts,' Abdul Hadi said. Dr. Asad Javaid, coordinator of the Pharmaceutical and Biomedical Research track, also praised the significance of this achievement, saying, 'The success of our first graduate is a powerful testament to the relevance and innovation embedded in our curriculum. This programme is designed to empower researchers to translate scientific discovery into practical solutions that address real-world health challenges. Nadin's achievement is just the beginning of the impact we aim to deliver—both in Qatar and beyond.' With this milestone, QU continues to expand its role as a leader in health research and innovation, contributing to the nation's long-term goals under Qatar National Vision 2030.
Malaysian Reserve
08-05-2025
- Business
- Malaysian Reserve
Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY
Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ — Syra Health Corp. (OTCQB: SYRA) ('Syra Health' or the 'Company'), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025. Q1 2025 Financial Highlights Total revenue of $1.9 million, up 6% compared to $1.8 million in Q1 2024. Revenues, excluding Healthcare Workforce, grew 261% YoY and expanded to 65% of total revenues, compared to 19% of total revenue in Q1 2024. Population Health reached $1.2 million in revenues, more than tripling from $333,000 in Q1 2024, driven by new contracts and extensions, as well as increased contributions from milestone-based revenues. Gross margins expand YoY by 14.6 percentage points to 31.7% in 1Q 2025. Operating Expense decreased 39% YoY, continuing to improve the profitability trajectory. Net Loss reduction to ($472,000) from ($1.4) million in Q1 2024. Cash of $2.5 million and no long-term debt as of March 31, 2025. Revenues, excluding Healthcare Workforce, grew 261% YoY and expanded to 65% of total revenues, compared to 19% of total revenue in Q1 2024. Population Health reached $1.2 million in revenues, more than tripling from $333,000 in Q1 2024, driven by new contracts and extensions, as well as increased contributions from milestone-based revenues. 2025 Financial Outlook Ongoing federal government-level budgetary revisions are impacting our key customers across state, local, and county government agencies. Given the current variability of the healthcare market, the Company believes it is prudent to withdraw its 2025 guidance at this time. An updated outlook will be provided once these changes are more quantifiable. The Company is continuing to prioritize the higher margin Population Health and Behavioral and Mental Health business units and is also expanding into the private healthcare sector, alongside its public sector work. Recent Operational Highlights Secured a $2.5 million Population Health contract with a major insurance provider to enhance member health plans using advanced data analytics. The contract, which is set to renew for two additional years at the same value, will be supported by a dedicated team of Syra Health professionals. Secured a one-year, $1.5 million contract extension with Indiana FSSA NeuroDiagnostic Institute, a portion of which has already been received, with the remainder to be recognized over time based on service needs. Awarded a $660,000 Population Health contract extension with a national healthcare organization to improve quality, enhance outcomes, and reduce costs through expert data analysis and member outreach supporting its Healthcare Effectiveness Data and Information Set (HEDIS®). Launched specialized content within Syrenity aimed at supporting individuals living with Post-Traumatic Stress Disorder (PTSD), including evidence-based coping strategies, guided exercises, and expert-led modules. Management Commentary Dr. Deepika Vuppalanchi, CEO of Syra Health, said, 'We are pleased that we began 2025 with strong momentum, delivering solid revenue growth and significant gross margin expansion, driven by our strategic focus on higher-margin business units. The success of our Population Health business unit underscores the effectiveness of our refined go-to-market strategy and our commitment to addressing critical gaps in healthcare delivery. As we navigate a dynamic healthcare landscape, we remain focused on operational efficiency, innovative digital health solutions, and long-term value creation for our key stakeholders.' Q1 2025 Financial Results Revenue for the first quarter of 2025 was $1.9 million, an increase of 6% compared to $1.8 million in the first quarter of 2024. Strong growth was driven by the high-margin Population Health segment, which expanded 261% year-over-year. Within Healthcare Workforce, our long-term contract with the Indiana FSSA NeuroDiagnostic Institute expired, partially offset by the aforementioned contract extension with the same customer. Gross profit margin was 31.7% in the first quarter of 2025, a 14.6 percentage point expansion compared to 17.1% in the prior year period. This improvement was related to the phase out of certain lower-margin Healthcare Workforce contracts and a shift towards higher-margin Population Health contracts. The year-over-year margin expansion also reflects a $120,000 reclassification of expenses from cost of services to selling, general, and administrative expenses in the year-ago period. Total operating expenses for the first quarter of 2025 were $1.1 million compared to $1.7 million in the first quarter of 2024, a decline of 39% compared to the year-ago period. The reduction was driven by operational efficiency gains and disciplined cost management, which was partially offset by the aforementioned reclassification of expenses. Adjusted EBITDA for the first quarter of 2025 was ($462,000), a significant improvement compared to ($1.4) million in the prior year. Net loss for the first quarter of 2025 was ($472,000) compared to ($1.4) million in the first quarter of 2024. This improvement of over 3x versus the year-ago period was driven by our operational restructuring efforts, a continuation of trends that began last year. Earnings per share for the first quarter of 2025 were ($0.04), compared to ($0.22) in the year-ago period. Conference Call Management will hold a conference call to discuss the full-year financial results at 9:00 am ET on May 8, 2025. Interested parties can listen to the live webcast and access the replay after the call through the same link available in the Investor Relations section of the Company's website at SYRA HEALTH SHEETS(UNAUDITED) March 31, December 31, 2025 2024 ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 2,490,585 $ 2,395,405 Accounts receivable, net 945,856 680,827 Other current assets 210,788 276,563 Total current assets 3,647,229 3,352,795 Property and equipment, net 20,550 27,347 Right-of-use asset 54,771 299,190 Total assets $ 3,722,550 $ 3,679,332 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 325,027 $ 101,690 Accrued expenses 211,867 230,383 Deferred revenue 599,213 16,611 Current portion of operating lease liability, related party 54,771 111,978 Notes payable 75,036 152,887 Total current liabilities 1,265,914 613,549 Non-current portion of operating lease liability, related party – 187,212 Total liabilities 1,265,914 800,761 Commitments and contingencies Stockholders' equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding – – Class A common stock, $0.001 par value, 100,000,000 sharesauthorized, 11,339,169 and 8,979,204 shares issued andoutstanding at March 31, 2025 and December 31, 2024,respectively 11,339 8,979 Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 6000,000 and 833,334 shares issued andoutstanding at March 31, 2025 and December 31, 2024,respectively 600 833 Additional paid-in capital 11,741,155 11,692,952 Accumulated deficit (9,296,458) (8,824,193) Total stockholders' equity (deficit) 2,456,636 2,878,571 Total liabilities and stockholders' equity (deficit) $ 3,722,550 $ 3,679,332 SYRA HEALTH OF OPERATIONS(UNAUDITED) For the Three Months Ended March 31, 2025 2024 Net revenues $ 1,857,774 $ 1,752,340 Cost of services 1,268,618 1,452,561 Gross profit 589,156 299,779 Operating expenses: Salaries and benefits 507,207 736,303 Professional services 224,026 194,580 Research and development expenses 37,173 277,548 Selling, general and administrative expenses 287,287 522,757 Depreciation 6,797 12,545 Total operating expenses 1,062,490 1,743,733 Operating loss (473,334) (1,443,954) Other income (expense): Interest income 4,298 981 Interest expense (3,229) (4,077) Total other income (expense) 1,069 (3,096) Net loss $ (472,265) $ (1,447,050) Weighted average common shares outstanding – basic and diluted 11,587,058 6,495,213 Net loss per common share – basic and diluted $ (0.04) $ (0.22) SYRA HEALTH OF CASH FLOWS(UNAUDITED) For the Three Months Ended March 31, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (472,265) $ (1,447,050) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 6,797 12,545 Common stock issued for services 2,586 18,875 Non-cash lease expense – 31,373 Stock-based compensation, stock options 32,944 14,140 Changes in operating assets and liabilities: Accounts receivable (265,029) 314,951 Accounts receivable, related party – (31,510) Other current assets 65,775 7,900 Right-of-use asset 244,419 – Accounts payable 223,337 182,576 Deferred revenue 582,602 6,108 Accrued expenses (18,516) 120,720 Operating lease liability (244,419) (31,373) Net cash provided by/(used in) operating activities 158,231 (800,745) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment – (5,619) Net cash used in investing activities – (5,619) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds received on exercise of warrants 14,800 850,129 Repayments on notes payable (77,851) (85,883) Net cash provided by/(used in) financing activities (63,051) 764,246 NET CHANGE IN CASH AND CASH EQUIVALENTS 95,180 (42,118) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 2,395,405 3,280,075 CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 2,490,585 $ 3,237,957 SUPPLEMENTAL INFORMATION: Interest paid $ 3,229 $ 4,077 Income taxes paid $ – $ – NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of Class B common stock to Class A common stock $ 2,333 $ – Non-GAAP Financial Measures In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ('GAAP'), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity, and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below. SYRA HEALTH OF ADJUSTED EBITDA TO NET LOSS(UNAUDITED) Quarter Ended March 31, 2024 March 31, 2025 Net Income ($1,447,050) ($472,265) Interest expense 4,077 3,229 Depreciation expense 12,545 6,797 Taxes – – Adjusted EBITDA ($1,430,428) ($462,239) About Syra Health Syra Health is a healthcare technology company that powers better health in critical areas such as mental health, population health, and the healthcare workforce. The company's leading-edge technology products and innovative services focus on prevention, access, and affordability. With a commitment to improving health, Syra Health is advancing healthcare solutions nationwide and around the world. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts For Media Inquiries:Christine DruryDirector of Corporate CommunicationsSyra Health463-345-5180christined@ For Investor Inquiries:Corbin WoodhullManaging Director, Global AdvisoryHayden IR602-476-1821corbin@
BBC News
18-03-2025
- Health
- BBC News
Effects of Covid pandemic playing out in North West five years on
Lancashire's Public Health Director says some health inequalities for the North West are now worse than they were before ill health, and crowded living conditions saw much of the region suffer more restrictions, illness and deaths than virtually anywhere else in the Sakthi Karunanithi says the pandemic led to a heightened awareness of the issues, but it hasn't necessarily led to action, although he says the current government does appear to be making moves to change Department of Health and Social Care says the government will tackle these issues "head on" and one of its first priorities "is to halve the gap in healthy life expectancy between the richest and poorest regions in England". It is now five years since the pandemic hit the UK but Dr Karunanithi said the effects of disrupted schooling, financial insecurity and social isolation were still playing out today."We've seen a rise in the impacts of overuse or misuse of substances, certainly with the younger generations we're seeing an impact on mental health and anxiety, depression and loneliness."There has also been a fall in the uptake of childhood and adult vaccinations, partly as a result of conspiracy theories about the Covid Karunanithi still vividly remembers the feeling of preparing for the unknown as Covid-19 spread through the country. 'Deprived communities were more affected' "We were working through the reasonable worst-case scenario and our preparedness for it and it then started to dawn on me – the heaviness of the type of messages we had to communicate," he said"That was one of the very difficult moments in my professional history."The pandemic brought public health issues into the spotlight"Everything we had known about what determines our health, what keeps us healthy, was in play. So where people lived, what types of job they did, how connected they were, all played a role in the spread of the virus," said Dr Karunanithi."More deprived communities, people who probably didn't have a choice to turn up at work, which we have a lot of in some parts of Lancashire, were significantly more affected than other people." A report in September 2021 by the Northern Health Science Alliance concluded that about half of the increased deaths of people with Covid and two-thirds of the increased mortalities from all causes were explained by higher deprivation and worse pre-pandemic health in the north of inequality also led to stricter restrictions than much of the rest of the country to try to control the high infection rates. Parts of Greater Manchester and East Lancashire were under almost continuous full or partial lockdown from March 2020 to March the announcement of a vaccine in December 2020 was greeted with joy and relief by many, who saw it as a chance to get back to Dr Helen Wall is the clinical director for Population Health in Greater Manchester. In late 2020 she was in charge of the Covid vaccine roll-out in Bolton. "People were being carried in, pushed in in wheelchairs, and elderly people were just crying, their relatives were crying because they'd been so scared of what was going on and they suddenly felt like there was hope. We all felt that," she said."Businesses would drop off food and drink and people would be knitting us masks."Dr Wall had spent much of the pandemic working at Covid clinics, and had seen hundreds of patients affected by the disease."I'd put people in ambulances and not been able to tell their relatives that they'd be alive by the time they got to the hospital, and the relatives couldn't go with them," she said. "I'd seen relatives banging on the ambulance door wanting to go with [the patients] because their oxygen was so low, and they felt they weren't going to make it."But while early adoption of the vaccines is widely credited with turning the tide on the pandemic in the UK, by the spring of 2021 it had become the target of conspiracy theorists – particularly after requirements were brought in for travel and some Wall said they started to get antivaxxers demonstrating outside the clinics."I started getting hate mail as did some of my colleagues. I got death threats… it became very very difficult to get through the hate that was being levelled."In 2018 90% of UK adults said vaccinations were safe and effective; by 2023 it was 70% according to research from the Vaccine Confidence Project, run by the London School of Hygiene and Tropical Medicine (LSHTM). 'Lessons learned haven't led to action' Dr Wall says she now sees the results in her job as a GP. "We get a lot more challenge back. People will have often seen things on social media, they will often have read things which for me are misinformation and mistruths, and it impacts on how they feel about vaccines."Nevertheless, she says the pandemic also prompted some change for the better. The use of vaccine buses, for example, sparked an increasing push to take treatments closer to communities."Certainly, in Greater Manchester we've used those theories a lot for things like cervical smears and all sorts of health interventions. We've looked at how we can take things to people rather than expect them to come to a health centre," she with vaccine take up, healthy life expectancy in the north west of England has also gone down - by more than two and a half years since 2019, far more than the national average. Dr Karunanithi said lessons learned during the pandemic about the importance of public health had not necessarily led to action. But he said he was hopeful that the current government was looking to change that."I do see a lot of rhetoric and commitment from the policy makers on shifting more towards prevention, doing more with our communities… innovation."But in an increasingly difficult financial climate, he stressed the importance of turning rhetoric into deeds."To improve health, we need to improve housing, the education, the economy more than, I would argue, just improving the NHS""When the resources aren't here it will come down to how we prioritise as a nation, how we prioritise as a society." A Department of Health and Social Care spokesperson said: "The pandemic impacted us all, with many people losing loved ones and people making great sacrifices to serve their community. "It also highlighted the shocking and appalling healthcare inequalities that exist within our systems.""Through our Plan for Change this government will tackle these inequalities head on. As part of this mission, one of our first priorities is to halve the gap in healthy life expectancy between the richest and poorest regions in England.""We are taking forward the lessons learnt from the pandemic and will continue to bolster our defences against global health threats." Listen to the best of BBC Radio Lancashire on BBC Sounds and follow BBC Lancashire on Facebook, X, and Instagram, and watch BBC North West Tonight on BBC iPlayer.
